BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy

• A leader in creating jobs through the advancement of RNA-based therapeutics
• A contributor to a high employment rate in Korea's healthcare industry

BOSTON, Dec. 15, 2022 /PRNewswire/ -- BIORCHESTRA ("BIORCHESTRA" or the "Company"), a RNA therapeutics company with offices in Daejeon, South Korea, and Cambridge, Massachusetts, USA and focused on neurodegenerative and rare genetic diseases, announced that the Company recently received a citation from the Korean Minister of Trade, Industry, and Energy at the 2022 Bio Entrepreneur Day, recognizing its contribution to a high employment rate in Korea's healthcare industry.

This award is granted by the Ministry of Trade, Industry, and Energy, with recommendations from Korea Bio and the Korean Evaluation Institute of Industrial Technology, to recognize companies that have made major contributions in 2022.

Dr. Branden Ryu, CEO and Founder of BIORCHESTRA, started the company with five scientists to expand on the work of his PhD thesis and identify novel pathways in neurodegeneration.  Having identified such a novel pathway and validating it in mice and higher animal models, the Company has developed a drug to address this pathway and has further developed an encapsulating and targeting delivery formulation to ensure its delivery to the central nervous system (CNS). Delivered in this manner, BIORCHESTRA's lead compound has been shown to reverse the phenotypic and cognitive manifestations of Alzheimer's Disease (AD) in relevant rodent and non-human primate models.

BIORCHESTRA is now a company of over 100 people based in Daejeon and Cambridge, Massachusetts, and is expanding beyond its lead compound to deliver drugs to the CNS for a variety of rare and neurodegenerative diseases. The Company has established relationships with a number of large and international pharmaceutical companies and, to support its internal and collaborative needs, has opened a research and development and manufacturing facility close to its headquarters in Daejeon.

Dr. Ryu affirmed, "BIORCHESTRA is developing innovative therapeutics that can go beyond the limits of already existing treatments, with disease-modifying benefits, by targeting the disease pathway itself early on rather than tackling its devastating pathophysiological damages. I believe we have validated our novel approach of attacking disease upstream of its manifestations. In developing this approach, we are expanding the use of our delivery technology to target other unaddressed diseases and partner with other companies who share our sense of urgency to address the needs of patients with neurodegerative and rare CNS diseases. On our own, and with partners, we are focused on changing the life trajectory of patients of all ages with these diseases."

About BIORCHESTRA Co., Ltd.

BIORCHESTRA, with offices in Daejeon, South Korea, and Cambridge, Massachusetts, USA, is a RNA-based therapeutics company focused on neurodegenerative and rare genetic diseases through the discovery of novel drug targets and the creation and development of an adaptive, tissue-specific drug delivery technology platform, BDDS^TM­ (BIORCHESTRA Drug Delivery System), for targeted delivery of therapeutics to specific organs such as brain and muscle.

BMD is the Company's lead RNA-based compound series in preclinical development targeting specific microRNAs which, in turn, regulate multiple messenger RNAs (mRNAs) centrally involved in disease pathophysiology initiation and progression. BIORCHESTRA believes that the exclusive targeting of a single pathological protein, such as Aβ in AD, may occur too late in the course of the disease. As BIORCHESTRA has demonstrated, the targeting of an upstream, specific microRNA signaling 'hub' via an anti-sense oligonucleotide holds the potential of reversing epigenetic changes and downstream pathophysiology and cognitive impairment in the AD brain. BIORCHESTRA also resolved the brain drug delivery challenge upon intravenous administration of the drug, through the successful development of a proprietary drug delivery system (BDDS™).

For further information visit:  www.biorchestra.com

Safe Harbor Statement

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

SOURCE BIORCHESTRA Co., Ltd.